Active management of Intrahepatic Cholestasis of Pregnancy is critical, since with active management the risk of stillbirth is thought to be about the same as an uncomplicated pregnancy. Active management may include many components, but the two most important are medication and early delivery.
1) Medication in the management plan of ICP.
Ursodeoxycholic Acid (UDCA, Ursodiol, Actigall)
The frontline treatment for Intrahepatic Cholestasis of Pregnancy is UDCA in doses of 600-2000mg per day. This medication has been shown to be superior to all other medications in the treatment of ICP, and has been shown to be safe for both mother and baby. Research has identified many ways in which it may help to protect the unborn baby until delivery can occur. UDCA works to reduce total bile acids in the bloodstream. It is, itself, a bile acid which is naturally produced in the body in small concentrations, but unlike other bile acids it is not toxic. It replaces the other toxic bile acids in the blood.
There are many other ways that this medication may help protect the baby, including preventing premature aging of the placenta, reducing risk of meconium staining, protecting the baby’s heart against changes induced by bile acids, restoring the placenta’s ability to transport bile acids away from the baby, and protecting cells from damage due to bile acids. Depending on the country, this medication may come by a different name (such as Ursofalk or Ursotan). If in doubt of the medication prescribed by your health care provider, perform a Google search of the medication that has been prescribed. The active ingredient should be Ursodeoxycholic acid.
In particularly stubborn cases, UDCA may be combined with additional medications to help control bile acids. It is important that these other medications are used in combination with UDCA and never instead of it. The following are other medications that are sometimes used.
Cholestyramine (Questran, Colestipol)
This medication was previously thought to be harmless to the unborn baby as it is not absorbed into the bloodstream. Instead, it remains in the digestive tract, binding excess bile acids there and removing them with the feces. It does not actively remove bile acids from the bloodstream. It is no longer recommended for use with Intrahepatic Cholestasis of Pregnancy, however, because it also binds fat-soluble vitamins, namely vitamin K. Since women with the disorder are already at risk for vitamin K deficiency, this can sometimes exacerbate the condition and lead to a higher risk of maternal hemorrhage. Sometimes cholestyramine is still prescribed in conjunction with UDCA. In these cases, the cholestyramine must not be taken within several hours of the UDCA since it will bind this medication and prevent it from being absorbed. It should also be prescribed with a vitamin K supplement, which must also be taken several hours away from the cholestyramine.
For some women, dexamethasone or other steroids may help reduce itching. However, it has been shown that UDCA is generally more effective. Steroids are also ineffective at reducing total bile acids. Additionally, repeated use of steroids during pregnancy may create problems with birth weight and brain development of the baby.
SAMe is not as effective as UDCA, but it is very effective when combined. It is a good choice to combine with UDCA when UDCA alone is not controlling bile acids well.
This medication is an antibiotic used to treat tuberculosis. It has the ability to reduce cholestatic symptoms for reasons that are unknown. It has never undergone clinical trials in pregnancy and it has many side effects, some of which can be serious. It is unknown how these side effects may affect the unborn baby, so it should only be used in the most severe cases. There has been one recent retrospective study which examined a small population that had been treated with combined UDCA and rifampin. In this small study, it appeared that combined treatment may reduce bile acids where UDCA alone did not.
Some providers choose to prescribe vitamin K to all Intrahepatic Cholestasis of Pregnancy patients. Others only do so when there is evidence of a deficiency such as abnormal clotting shown in PT (prothrombin time) and/or PTT (partial thromboplastin time) tests, abnormal bruising, or pale stools.
2) Early Delivery in the management plan of ICP.
Since it is not possible to predict which pregnancies are at risk for stillbirth, it is recommended that all ICP pregnancies, both mild and severe, be delivered early, even if serum bile acids return to normal after treatment with UDCA. In most cases, delivery will occur at 36-37 weeks gestation. In some mild cases, proviers may recommend delivery as late as 38 weeks gestation. In some cases, when Intrahepatic Cholestasis of Pregnancy is not well-controlled, providers may choose to deliver even earlier. Exact timing of delivery can be difficult, as it means balancing the risks of the disorder with the risks of early delivery. It is known that most stillbirths tend to cluster between 37-39 weeks, which is why delivery is recommended to occur prior to this gestation.
One concern women often have when confronted with early delivery is the risk of Cesarean section. It has been shown in studies that women with Intrahepatic Cholestasis of Pregnancy are not at increased risk of Cesarean section, even when they deliver early. This is largely due to the fact that the disorder makes the uteruses more sensitive to the hormone oxytocin (Pitocin), making it easier to start labor.
Understand that it is normal to have worries and concerns about early delivery. It can be a difficult concept to come to terms with, but in cases of Intrahepatic Cholestasis of Pregnancy it is recommended to protect the baby against the risk of stillbirth.
3) Additional management plan of ICP.
The medication UDCA and early delivery, typically at 36-37 weeks, are considered by many providers to be the two most important parts of your management plan. There are many other types of monitoring which may be performed to give the health care provider more information regarding the condition of the mother and the baby.
Most healthcare providers will choose to monitor your bile acids once or twice weekly during the time between diagnosis and delivery. This monitoring is recommended because if it is found that bile acids are not being well-controlled adjustments can be made to your treatment plan, including increasing the dosage of UDCA, adding a second medication such as SAMe, or delivering earlier than previously planned. In many cases, liver functions will also be monitored to provide the healthcare provider with information regarding how the mother is coping with the pregnancy. Elevated liver functions do not pose a risk to the baby.
If there is a concern that the mother may be suffering from vitamin K deficiency, the provider may run tests to check to see if blood is clotting normally. These tests are PT (prothrombin time) and PTT (partial thromboplastin time). If these are abnormal the deficiency can be corrected with oral vitamin K supplements.
Fetal monitoring cannot completely eliminate the risk of stillbirth, and research has not been able to identify the type, duration, or frequency which should be used. Using fetal monitoring in place of early delivery is not advised since there are reports of stillbirths occurring within hours of reassuring monitoring. However, if it is discovered that the baby is distressed during monitoring, the provider may choose to deliver earlier than originally planned. Since there is little risk and potential benefit to fetal monitoring, it is recommended for Intrahepatic Cholestasis of Pregnancy. Fetal monitoring may include:
- CTG (cardiotopography)/NST (non-stress test) – examines the fetal heart rate to check for abnormalities which may indicate distress.
- BPP (biophysical profile) – a more in depth and complete examination which uses ultrasound to measure several different factors that may indicate distress.
- Doppler flow studies – uses a specialized ultrasound machine to examine blood flow in umbilical arteries and veins as well as the blood vessels in baby’s organs. This is most often done when an intrauterine growth restriction – when baby measures smaller than expected – has been noted.
Steroid injections (e.g. betamethasone)
ACOG (American Congress of Obstetrics and Gynecology) and SMFM (Society of Maternal-Fetal Medicine) now recommend that steroid injections be administered when delivery is expected to occur prior to 37 weeks gestation. This is typically done as a series of two injections twenty-four hours apart. It is important to understand that steroid injections are most effective when given at least 24 hours and no more than 7 days prior to delivery. If delivery does not occur within 7 days, the injections cannot be repeated.
Some providers choose to perform an amniocentesis, where a small amount of the fluid which cushions the baby is extracted using a special needle, to determine whether or not the baby’s lungs are mature prior to delivery. This may help determine when is the best time to deliver. Other providers do not recommend the amniocentesis because they believe that delivery is necessary at a certain gestation regardless of whether the lungs are mature. Most babies’ lungs are mature at 34 weeks gestation.